Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Published Online: 2020-06-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Anne Uyei•Caroline Robert•Daniil Stroyakovskiy•Georgy Moiseevich Manikhas•Grant A McArthur•Helen Gogas•Karl Lewis•Kuan-Chieh Huang•Lev Demidov•Paolo A Ascierto•Piotr Rutkowski•Ralf Gutzmer•Rodrigo P Pereira•Svetlana Protsenko•Thomas Eigentler•Virginia McNally•Yibing Yan
